Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection)

Inclusion Criteria: Healthy Participants SAD: * Male participants weighed ≥ 50.0 kg, female participants weighed ≥ 45.0 kg; * Participants were healthy individuals; * Participants promise to have no plans to have a child, donate sperm or eggs and voluntarily take effective non-drug contraception measures during the trial and within 3 months after the end of the trial; Participants with Chronic HBV infection, MAD: * Chronic HBV infection, and HBeAg negative; * Patients who had received antiviral therapy for at least one year before screening and stabilization therapy with nucleoside (nucleotide) reverse transcriptase inhibitors for ≥ 3 months before screening (nucleoside (nucleotide) reverse transcriptase inhibitors; Exclusion Criteria: * Participants with a history of active pathological hemorrhage or those with bleeding tendency, or those with a history of neurological disease; * Participants with major trauma or major surgery within 3 months before trial screening; * Participants with a history of drug allergy; * Participants who used any drugs before trial screening or are using any drugs, including vitamins and Chinese herbal medicines; * Participants with abnormal results of ECG examination, laboratory test in the screening period which were judged as clinically significant; * Participants who cannot tolerate subcutaneous injection; * Patients with a previous clinical diagnosis of liver cirrhosis, or a history of alcoholic liver disease, autoimmune liver disease, inherited metabolic liver disease, and other liver diseases; * Participants with a clinically significant acute infection; * Women who were pregnant or lactating or had a positive pregnancy test result;